Interpace Biosciences, Inc. (IDXG)
- Previous Close
1.4225 - Open
1.4550 - Bid --
- Ask --
- Day's Range
1.3400 - 1.5400 - 52 Week Range
0.6203 - 3.5400 - Volume
5,677 - Avg. Volume
5,663 - Market Cap (intraday)
6.565M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
6.00 - EPS (TTM)
0.2500 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
www.interpace.com108
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IDXG
Performance Overview: IDXG
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IDXG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IDXG
Valuation Measures
Market Cap
6.23M
Enterprise Value
13.92M
Trailing P/E
5.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.15
Price/Book (mrq)
--
Enterprise Value/Revenue
0.35
Enterprise Value/EBITDA
3.72
Financial Highlights
Profitability and Income Statement
Profit Margin
1.99%
Return on Assets (ttm)
12.12%
Return on Equity (ttm)
--
Revenue (ttm)
40.21M
Net Income Avi to Common (ttm)
1.11M
Diluted EPS (ttm)
0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
4.22M